Plus Cash vs Total Stockholder Equity Analysis

PSTV Stock  USD 1.35  0.04  3.05%   
Plus Therapeutics financial indicator trend analysis is much more than just breaking down Plus Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Plus Therapeutics is a good investment. Please check the relationship between Plus Therapeutics Cash and its Total Stockholder Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Cash vs Total Stockholder Equity

Cash vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Plus Therapeutics Cash account and Total Stockholder Equity. At this time, the significance of the direction appears to have weak relationship.
The correlation between Plus Therapeutics' Cash and Total Stockholder Equity is 0.3. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Plus Therapeutics, assuming nothing else is changed. The correlation between historical values of Plus Therapeutics' Cash and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Plus Therapeutics are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Cash i.e., Plus Therapeutics' Cash and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.3
Relationship DirectionPositive 
Relationship StrengthVery Weak

Cash

Cash refers to the most liquid asset of Plus Therapeutics, which is listed under current asset account on Plus Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Plus Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Plus Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.
Most indicators from Plus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Plus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Plus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.At this time, Plus Therapeutics' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 9.1 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.09) in 2024.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization419K712K628K968.9K
Cost Of Revenue66K712K9.7M10.2M

Plus Therapeutics fundamental ratios Correlations

0.940.430.170.720.72-0.510.850.860.85-0.470.46-0.450.080.670.290.690.7-0.020.020.150.60.340.50.6-0.69
0.940.190.430.550.55-0.580.870.90.71-0.350.52-0.410.170.770.380.760.76-0.23-0.090.220.590.240.420.61-0.63
0.430.19-0.20.30.3-0.370.03-0.040.32-0.240.0-0.05-0.070.290.150.040.210.160.230.040.30.180.230.26-0.31
0.170.43-0.2-0.5-0.5-0.410.120.24-0.30.410.46-0.050.170.790.540.240.52-0.37-0.150.40.31-0.39-0.040.38-0.08
0.720.550.3-0.51.0-0.090.720.680.97-0.710.09-0.35-0.02-0.02-0.130.50.230.090.01-0.140.230.580.460.2-0.56
0.720.550.3-0.51.0-0.10.720.680.97-0.710.09-0.35-0.02-0.02-0.130.50.230.090.01-0.140.230.580.460.2-0.56
-0.51-0.58-0.37-0.41-0.09-0.1-0.39-0.24-0.20.15-0.16-0.28-0.5-0.62-0.37-0.45-0.580.330.25-0.27-0.38-0.190.16-0.390.11
0.850.870.030.120.720.72-0.390.890.81-0.570.15-0.470.310.470.060.730.71-0.13-0.27-0.190.570.50.250.58-0.57
0.860.9-0.040.240.680.68-0.240.890.81-0.40.51-0.480.050.540.210.70.62-0.11-0.120.130.490.270.490.51-0.66
0.850.710.32-0.30.970.97-0.20.810.81-0.640.24-0.430.020.20.00.630.410.08-0.02-0.060.370.510.50.35-0.65
-0.47-0.35-0.240.41-0.71-0.710.15-0.57-0.4-0.640.230.11-0.280.03-0.02-0.24-0.20.170.250.21-0.07-0.97-0.07-0.070.15
0.460.520.00.460.090.09-0.160.150.510.240.23-0.15-0.370.530.530.30.190.050.370.810.1-0.370.590.11-0.33
-0.45-0.41-0.05-0.05-0.35-0.35-0.28-0.47-0.48-0.430.11-0.150.41-0.22-0.01-0.25-0.19-0.23-0.380.31-0.260.04-0.61-0.230.73
0.080.17-0.070.17-0.02-0.02-0.50.310.050.02-0.28-0.370.410.170.020.450.51-0.32-0.92-0.30.180.47-0.80.210.4
0.670.770.290.79-0.02-0.02-0.620.470.540.20.030.53-0.220.170.550.430.8-0.2-0.080.350.63-0.080.20.66-0.41
0.290.380.150.54-0.13-0.13-0.370.060.210.0-0.020.53-0.010.020.550.160.11-0.170.040.580.07-0.020.150.09-0.12
0.690.760.040.240.50.5-0.450.730.70.63-0.240.3-0.250.450.430.160.59-0.21-0.39-0.010.350.210.070.38-0.35
0.70.760.210.520.230.23-0.580.710.620.41-0.20.19-0.190.510.80.110.59-0.23-0.43-0.050.730.21-0.060.76-0.31
-0.02-0.230.16-0.370.090.090.33-0.13-0.110.080.170.05-0.23-0.32-0.2-0.17-0.21-0.230.36-0.260.11-0.210.16-0.02-0.22
0.02-0.090.23-0.150.010.010.25-0.27-0.12-0.020.250.37-0.38-0.92-0.080.04-0.39-0.430.360.32-0.11-0.440.75-0.16-0.35
0.150.220.040.4-0.14-0.14-0.27-0.190.13-0.060.210.810.31-0.30.350.58-0.01-0.05-0.260.32-0.16-0.30.36-0.120.05
0.60.590.30.310.230.23-0.380.570.490.37-0.070.1-0.260.180.630.070.350.730.11-0.11-0.160.030.160.99-0.39
0.340.240.18-0.390.580.58-0.190.50.270.51-0.97-0.370.040.47-0.08-0.020.210.21-0.21-0.44-0.30.03-0.180.040.03
0.50.420.23-0.040.460.460.160.250.490.5-0.070.59-0.61-0.80.20.150.07-0.060.160.750.360.16-0.180.14-0.74
0.60.610.260.380.20.2-0.390.580.510.35-0.070.11-0.230.210.660.090.380.76-0.02-0.16-0.120.990.040.14-0.34
-0.69-0.63-0.31-0.08-0.56-0.560.11-0.57-0.66-0.650.15-0.330.730.4-0.41-0.12-0.35-0.31-0.22-0.350.05-0.390.03-0.74-0.34
Click cells to compare fundamentals

Plus Therapeutics Account Relationship Matchups

Plus Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets23.2M12.1M22.0M23.9M11.4M10.8M
Short Long Term Debt Total11.9M7.0M7.0M5.6M4.2M4.0M
Total Stockholder Equity1.2M3.0M10.8M6.4M(1.3M)(1.3M)
Net Debt(5.7M)(1.4M)(11.4M)(12.5M)(4.4M)(4.6M)
Cash17.6M8.3M18.4M18.1M8.6M14.2M
Cash And Short Term Investments17.6M8.3M18.4M18.1M8.6M14.1M
Common Stock Shares Outstanding92.3K295.2K805.9K1.8M3.1M3.3M
Liabilities And Stockholders Equity23.2M12.1M22.0M23.9M11.4M10.8M
Non Current Liabilities Total7.6M535K5.3M5.6M2.0M1.9M
Total Liab22.1M9.1M11.1M17.4M12.7M25.2M
Total Current Assets19.8M9.2M19.7M21.8M9.8M17.1M
Other Current Liab6K1.3M1.4M1.7M1.9M2.0M
Total Current Liabilities14.5M8.5M5.9M11.9M10.7M10.5M
Property Plant And Equipment Net3.0M2.5M1.8M1.6M1.1M2.0M
Retained Earnings(425.3M)(433.5M)(446.9M)(467.2M)(480.5M)(456.5M)
Non Current Assets Total3.4M2.9M2.3M2.1M1.6M1.5M
Non Currrent Assets Other11.7M72K16K12K32K30.4K
Net Receivables233K1.2M59K7K6.3K6.0K
Other Current Assets957K770K1.3M3.7M1.3M1.2M
Other Stockholder Equity426.4M436.5M457.7M473.6M479.1M286.3M
Short Term Debt11.2M6.5M1.8M1.8M4.1M4.6M
Common Stock4K7K16K34K5K4.8K
Current Deferred Revenue1.9M2.9M1.3M1.4M1.3M1.2M
Accounts Payable327K789K2.6M8.4M4.8M5.0M
Property Plant And Equipment Gross3.0M2.5M1.8M1.6M3.6M2.1M
Net Tangible Assets788K2.6M10.4M6.0M6.9M3.8M
Capital Surpluse413.3M418.4M426.4M436.5M502.0M424.5M
Property Plant Equipment2.2M1.8M1.8M1.6M1.8M2.0M
Other Assets72K652K16K12K10.8K10.3K
Other Liab6.9M7K1K1.6M1.9M1.4M
Capital Lease Obligations913K661K380K251K205K294.6K
Short Long Term Debt14.2M11.1M6.3M1.6M4.0M5.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.